<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-15.8'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//www.biotechreality.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://www.biotechreality.com/2026/06/wegovy-pill-uae-launch.html</loc>
  <lastmod>2026-06-03T18:28:28Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Novo Nordisk Launches Wegovy Pill in the UAE</news:title>
   <news:publication_date>2026-06-03T18:24:32Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/06/astrazeneca-camizestrant-breast-cancer-treatment-serena.html</loc>
  <lastmod>2026-06-02T19:20:02Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>AstraZeneca Camizestrant Breast Cancer Treatment Delays Disease Progression by 55%</news:title>
   <news:publication_date>2026-06-02T19:19:59Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/06/roche-giredestrant-fda-review.html</loc>
  <lastmod>2026-06-02T18:47:26Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>FDA Accepts Priority Review for Roche Giredestrant in Early-Stage Breast Cancer</news:title>
   <news:publication_date>2026-06-02T18:16:00Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/06/roche-obesity-portfolio-enicepatide-petrelintide-ada-2026.html</loc>
  <lastmod>2026-06-01T18:27:44Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>Roche Obesity Portfolio Forges Ahead as Enicepatide and Petrelintide Show Landmark Phase II Efficacy</news:title>
   <news:publication_date>2026-06-01T18:27:40Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://www.biotechreality.com/2026/06/novartis-scemblix-cml-treatment.html</loc>
  <lastmod>2026-06-01T17:44:13Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>BiotechReality - Information Intelligence System for Biopharma</news:name>
    <news:language>en</news:language>
   </news:publication>
   <news:title>New 144-Week Data Affirms Superiority of Novartis Scemblix CML Treatment</news:title>
   <news:publication_date>2026-06-01T17:44:06Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
